ntage of the mean survival time (MST) of rol group after measuring MST:

$$T/C = \frac{MST \text{ of the test group}}{MST \text{ of the control group}} \times 100 (\%)$$

The T/C value of the compound in Example 3 at a dose of 25 mg/kg was 243% whereas the T/C value of 2'-deoxy-2'methylidenecytidine at the same dose was 152%.

We claim:

1. A pyrimidine 2'-deoxy-2'methylidene nucleoside compound of the formula:

wherein R¹ represents amino [or], hydroxy or acylamino having 2 to 30 carbon atoms; R² represents hydrogen, halogen, a lower alkyl, a lower alkenyl, a lower alkynyl or a haloalkyl; R³ and R⁴ may be the same or different and represent hydrogen, [stearoyl] acyl having 2 to 30 carbon atoms or aminoacyl, or a pharmaceutically acceptable salt or hydrate thereof, [except] excluding the case [that] where R¹ is amino or hydroxy, and both of R³ and R⁴ [may be] are hydrogen.

- 2. A compound or a pharmaceutically acceptable salt or hydrate thereof as claimed in claim 1 which is selected from the group consisting of 2'-deoxy2'-methylidene-5'-0-stearoylcytidine and 5'-0-(2-amino-3-methylvaleryl)-2'-deoxy-2'-methylidenecytidine.
- 3. A pyrimidine 2'-deoxy-2'-methylidene nucleoside compound or a pharmaceutically acceptable salt or hydrate thereof as claimed in Claim 1, which is 2'-deoxy-2'-methylidene-N⁴-decanoylcytidine.
- 4. A pyrimidine 2'-deoxy-2'-methylidene nucleoside compound or a pharmaceutically acceptable salt or hydrate thereof as claimed in Claim 1, which is 2'-deoxy-2'-methylidene-N⁴-stearoylcytidine.
- 5. A pyrimidine 2'-deoxy-2'-methylidene nucleoside compound or a pharmaceutically acceptable salt or hydrate thereof as claimed in Claim 1, which is 5'-0-decanoyl-2'-deoxy-2'-methylidenecytidine.
- 6. A pyrimidine 2'-deoxy-2'-methylidene nucleoside compound or a pharmaceutically acceptable salt or hydrate thereof as claimed in Claim 1, which is 5'-0-myristoyl-2'-deoxy-2'-methylidenecytidine.
- 7. A pyrimidine 2'-deoxy-2'-methylidene nucleoside compound or a pharmaceutically acceptable salt or hydrate thereof as claimed in claim 1, which is 5'-o-palmitoyl-2'-deoxy-2'-methylidenecytidine.
- 8. A pyrimidine 2'-deoxy-2'-methylidene nucleoside compound or a pharmaceutically acceptable salt or hydrate thereof as claimed in Claim 1, which is 2'-deoxy-2'-methylidene-5'-0-stearoyleytidine.
- 9. A composition comprising a compound or a pharmaceutically acceptable salt or hydrate thereof as claimed in Claim 1.
- 10. A composition for oral administration comprising a compound or a pharmaceutically acceptable salt or hydrate thereof as claimed in Claim 1.

addy